Ascletis Pharma becomes first firm to file for IPO under new rules in Hong Kong

May 11, 2018
New regime allows biotech firms without profit or revenue to list
Ascletis Pharma has become the first biotechnology firm to file for an IPO in Hong Kong following recent reforms that allow biotech firms without profit or revenue to list. The Hangzhou-based company submitted a highly redacted application for a listing published

Content Preview

to continue reading

Register
  • Unlimited news online
  • Newsletter
Free
Sign up to get stories direct to your inbox
logo-black logo-black
Loading